Toll-like receptor 4 mediates Lewis lung carcinoma-induced muscle wasting via coordinate activation of protein degradation pathways

[1]  Hongliang Li,et al.  The innate immune signaling in cancer and cardiometabolic diseases: Friends or foes? , 2017, Cancer letters.

[2]  M. Muscaritoli,et al.  Autophagy is induced in the skeletal muscle of cachectic cancer patients , 2016, Scientific Reports.

[3]  M. Swarbrick,et al.  Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia. , 2016, Seminars in cell & developmental biology.

[4]  Ashok Kumar,et al.  Inhibition of ER stress and unfolding protein response pathways causes skeletal muscle wasting during cancer cachexia , 2016, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  R. Schwabe,et al.  Damage-associated molecular patterns in cancer: A double-edged sword , 2016, Oncogene.

[6]  K. Fearon.  Cachexia: Treat wasting illness on multiple fronts , 2016, Nature.

[7]  J. Ross,et al.  Evaluating potential biomarkers of cachexia and survival in skeletal muscle of upper gastrointestinal cancer patients , 2015, Journal of cachexia, sarcopenia and muscle.

[8]  Derya Demirtas,et al.  The prognostic role of inflammation and hormones in patients with metastatic cancer with cachexia , 2015, Medical Oncology.

[9]  T. Mukohara,et al.  Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer , 2014, PloS one.

[10]  A. Dingemans,et al.  Phase II drugs that are currently in development for the treatment of cachexia , 2014, Expert opinion on investigational drugs.

[11]  D. Guttridge,et al.  Modeling human cancer cachexia in colon 26 tumor-bearing adult mice , 2014, Journal of cachexia, sarcopenia and muscle.

[12]  C. Croce,et al.  Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7 , 2014, Proceedings of the National Academy of Sciences.

[13]  J. Carson,et al.  Skeletal muscle glycoprotein 130's role in Lewis lung carcinoma–induced cachexia , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  D. Marks,et al.  Cancer‐ and endotoxin‐induced cachexia require intact glucocorticoid signaling in skeletal muscle , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[15]  A. Dingemans,et al.  Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia. , 2013, The American journal of clinical nutrition.

[16]  Y. Kwon,et al.  Signaling mechanism of tumor cell‐induced up‐regulation of E3 ubiquitin ligase UBR2 , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  P. Costelli,et al.  Autophagic degradation contributes to muscle wasting in cancer cachexia. , 2013, The American journal of pathology.

[18]  Guohua Zhang,et al.  p38β MAPK upregulates atrogin1/MAFbx by specific phosphorylation of C/EBPβ , 2012, Skeletal Muscle.

[19]  Sean H. Adams,et al.  Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways[S] , 2012, Journal of Lipid Research.

[20]  D. Glass,et al.  Cancer cachexia: mediators, signaling, and metabolic pathways. , 2012, Cell metabolism.

[21]  T. Zimmers,et al.  JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. , 2012, American journal of physiology. Endocrinology and metabolism.

[22]  Guohua Zhang,et al.  C/EBPβ mediates tumour‐induced ubiquitin ligase atrogin1/MAFbx upregulation and muscle wasting , 2011, The EMBO journal.

[23]  Alexander Doyle,et al.  Toll‐like receptor 4 mediates lipopolysaccharide‐induced muscle catabolism via coordinate activation of ubiquitin‐proteasome and autophagy‐lysosome pathways , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  P. Hasselgren,et al.  Dexamethasone and corticosterone induce similar, but not identical, muscle wasting responses in cultured L6 and C2C12 myotubes , 2008, Journal of cellular biochemistry.

[25]  D. Guttridge,et al.  The effect of altered Toll-like receptor 4 signaling on cancer cachexia. , 2007, Archives of otolaryngology--head & neck surgery.

[26]  A. Sharafkhaneh,et al.  Toll-like receptor 4 is a sensor for autophagy associated with innate immunity. , 2007, Immunity.

[27]  J. Flier,et al.  TLR4 links innate immunity and fatty acid-induced insulin resistance. , 2006, The Journal of clinical investigation.

[28]  J. Boyd,et al.  Toll-Like Receptors Differentially Regulate CC and CXC Chemokines in Skeletal Muscle via NF-κB and Calcineurin , 2006, Infection and Immunity.

[29]  J. B. Kim,et al.  Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. , 2006, Biochemical and biophysical research communications.

[30]  P. Goggin,et al.  Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial , 2005, Gut.

[31]  D. Mann,et al.  TNF-acts via p 38 MAPK to stimulate expression of the ubiquitin ligase atrogin 1 / MAFbx in skeletal muscle , 2005 .

[32]  S. Akira,et al.  Toll-like receptors in innate immunity. , 2004, International immunology.

[33]  W. Frontera,et al.  IKKβ/NF-κB Activation Causes Severe Muscle Wasting in Mice , 2004, Cell.

[34]  C. Lang,et al.  Endotoxin Stimulates In Vivo Expression of Inflammatory Cytokines Tumor Necrosis Factor Alpha, Interleukin-1&bgr;, -6, and High-Mobility-Group Protein-1 in Skeletal Muscle , 2003, Shock.

[35]  A. Goldberg,et al.  TNF‐α increases ubiquitin‐conjugating activity in skeletal muscle by up‐regulating UbcH2/E220k , 2003 .

[36]  S. Akira,et al.  Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.

[37]  P Bailey,et al.  Double Edged Sword , 2002 .

[38]  J. O'fallon,et al.  Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Goldberg,et al.  Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. , 1995, The American journal of physiology.

[40]  Jun Wada,et al.  Innate immunity in diabetes and diabetic nephropathy , 2016, Nature Reviews Nephrology.

[41]  F. López‐Soriano,et al.  Counteracting inflammation: a promising therapy in cachexia. , 2012, Critical reviews in oncogenesis.

[42]  Wan-Wan Lin,et al.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis , 2009, Nature.

[43]  P. Malfertheiner,et al.  A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. , 2008, The journal of supportive oncology.

[44]  J. Boyd,et al.  Toll-like receptors differentially regulate CC and CXC chemokines in skeletal muscle via NF-kappaB and calcineurin. , 2006, Infection and immunity.

[45]  W. Frontera,et al.  IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. , 2004, Cell.

[46]  A. Goldberg,et al.  TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  S. Hampson.  Randomised, placebo-controlled trial , 2002 .